Sunday, September 13, 2026

Biotech & Pharma

1 article

Jade Biosciences Eyes Phase 1 Launch for JADE301 as Autoimmune Pipeline Takes Shape

Jade Biosciences has outlined plans to initiate a Phase 1 clinical trial for JADE301, its monoclonal antibody candidate targeting autoimmune diseases, with the trial expected to commence by March 2027. The milestone represents a critical de-risking event for the company's broader pipeline strategy, as the biotech looks to establish itself in the competitive but lucrative autoimmune therapeutics market. Investors in the clinical-stage space will be watching the trial initiation as a key inflectio

ViaNews Editorial Team (Finance)•Feb 18, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet

A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

JPMorgan Chase & Co.

Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,981

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,981 facts checked against source5,280 source documents archived

Query this data → isubstrate.com